News

Stopping Dasatinib and Nilotinib Explored in Chronic Myeloid Leukemia

Publish date: July 6, 2011

 

FROM THE ANNUAL CONGRESS OF THE EUROPEAN HEMATOLOGY ASSOCIATION

Dr. Réa disclosed serving on advisory boards of Bristol-Myers Squibb and Novartis.

Pages

Recommended Reading

Horse ATG for Severe Aplastic Anemia
MDedge Hematology and Oncology
Nilotinib for Myeloid Leukemia
MDedge Hematology and Oncology
CML Treatment: Old Drug, New Name
MDedge Hematology and Oncology
Higher Methotrexate Dose Fends Off Pediatric Leukemia Recurrence
MDedge Hematology and Oncology
CASE LETTER Hydroxyurea-induced palmar-plantar erythrodysesthesia in an adult with sickle cell disease
MDedge Hematology and Oncology
Underreporting of neutropenic toxicity associated with current treatment regimens for selected hematologic malignancies
MDedge Hematology and Oncology
Second-line CML drugs prove better than first
MDedge Hematology and Oncology
Treatment of CML continues to progress
MDedge Hematology and Oncology
ODAC votes against one leukemia, one NHL drug
MDedge Hematology and Oncology
Fostamatinib successfully targets the B-cell receptor
MDedge Hematology and Oncology